Longeveron, a clinical-stage biotechnology company developing anti-aging treatments, went public Friday.
The Miami-based company (Nasdaq: LGVN), founded in 2014, seeks to raise $26.6 million through an initial public offering of 2.66 million shares starting at $10 each. The IPO is expected to close Feb. 17.
